Int J Geriatr Psychiatry. 2000 May;15(5):387-92.

Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings from an open trial.

McKeith IG, Grace JB, Walker Z, Byrne EJ, Wilkinson D, Stevens T, Perry EK.

Source

Institute for the Health of the Elderly, Wolfson Research Centre, Newcastle General Hospital, Newcastle upon Tyne, UK.

Abstract

The objective of this study was to assess the tolerability and efficacy of rivastigmine in a group of patients with probable dementia with Lewy bodies (DLB), using an open label study. Open label treatment was with rivastigmine up to maximum tolerated dose (mean 9.6 mg daily, range 3-12 mg). Eleven patients with DLB, mean age 78.5 years, were treated with this cholinesterase inhibitor. After 12 weeks of treatment, mean Neuropsychiatric Inventory scores fell by 73% for delusions, 63% for apathy, 45% for agitation and 27% for hallucinations. Five of the patients (45%) experienced very significant clinical improvements that had not been achieved with other treatments, including low dose neuroleptics. Medication was well tolerated and parkinsonian symptoms tended to improve. Cholinesterase inhibition may be a safe and effective alternative to neuroleptic treatment in DLB. Such effects may also prove to be applicable to the management of neuropsychiatric symptoms in Parkinson's disease and Alzheimer's disease.

PMID:: 10822236; [PubMed - indexed for MEDLINE]

LinkOut - more resources

Full Text Sources

Other Literature Sources

COS Scholar Universe

Medical

Supplemental Content

Save items

Related citations in PubMed

Review Cholinesterase inhibitors for dementia with Lewy bodies. [Cochrane Database Syst Rev. 2003]
Review Cholinesterase inhibitors for dementia with Lewy bodies.
Wild R, Pettit T, Burns A. Cochrane Database Syst Rev. 2003; (3):CD003672.
Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. [Lancet. 2000]
Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study.
McKeith I, Del Ser T, Spano P, Emre M, Wesnes K, Anand R, Cicin-Sain A, Ferrara R, Spiegel R. Lancet. 2000 Dec 16; 356(9247):2031-6.
Long-Term use of rivastigmine in patients with dementia with Lewy bodies: an open-label trial. [Int Psychogeriatr. 2001]
Long-Term use of rivastigmine in patients with dementia with Lewy bodies: an open-label trial.
Grace J, Daniel S, Stevens T, Shankar KK, Walker Z, Byrne EJ, Butler S, Wilkinson D, Woolford J, Waite J, et al. Int Psychogeriatr. 2001 Jun; 13(2):199-205.
Dementia with Lewy bodies treated with rivastigmine: effects on cognition, neuropsychiatric symptoms, and sleep. [Int Psychogeriatr. 2001]
Dementia with Lewy bodies treated with rivastigmine: effects on cognition, neuropsychiatric symptoms, and sleep.
Maclean LE, Collins CC, Byrne EJ. Int Psychogeriatr. 2001 Sep; 13(3):277-88.
Review Effects of rivastigmine on behavioral and psychological symptoms of dementia in Alzheimer's disease. [Clin Ther. 2004]
Review Effects of rivastigmine on behavioral and psychological symptoms of dementia in Alzheimer's disease.
Finkel SI. Clin Ther. 2004 Jul; 26(7):980-90.

See reviews... See all...

Cited by 3 PubMed Central articles

Association cortex hypoperfusion in mild dementia with Lewy bodies: a potential indicator of cholinergic dysfunction? [Brain Imaging Behav. 2011]
Association cortex hypoperfusion in mild dementia with Lewy bodies: a potential indicator of cholinergic dysfunction?
Fong TG, Inouye SK, Dai W, Press DZ, Alsop DC. Brain Imaging Behav. 2011 Mar; 5(1):25-35.
1H MR spectroscopy in common dementias. [Neurology. 2004]
1H MR spectroscopy in common dementias.
Kantarci K, Petersen RC, Boeve BF, Knopman DS, Tang-Wai DF, O'Brien PC, Weigand SD, Edland SD, Smith GE, Ivnik RJ, et al. Neurology. 2004 Oct 26; 63(8):1393-8.
Review Dementia with Lewy bodies. Review of diagnosis and pharmacologic management. [Can Fam Physician. 2003]
Review Dementia with Lewy bodies. Review of diagnosis and pharmacologic management.
Frank C. Can Fam Physician. 2003 Oct; 49:1304-11.

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings...
Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings from an open trial.
Int J Geriatr Psychiatry. 2000 May ;15(5):387-92.

PubMed
Effects of age on serum dehydroepiandrosterone sulfate, IGF-I, and IL-6 levels i...
Effects of age on serum dehydroepiandrosterone sulfate, IGF-I, and IL-6 levels in women.
Calcif Tissue Int. 2000 Jun ;66(6):414-8.

PubMed
Determinants of cytochrome c pro-apoptotic activity. The role of lysine 72 trime...
Determinants of cytochrome c pro-apoptotic activity. The role of lysine 72 trimethylation.
J Biol Chem. 2000 May 26 ;275(21):16127-33.

PubMed
Substitutions at codon 22 of Alzheimer's abeta peptide induce diverse conformati...
Substitutions at codon 22 of Alzheimer's abeta peptide induce diverse conformational changes and apoptotic effects in human cerebral endothelial cells.
J Biol Chem. 2000 Sep 1 ;275(35):27110-6.

PubMed
The retinal determination gene, dachshund, is required for mushroom body cell di...
The retinal determination gene, dachshund, is required for mushroom body cell differentiation.
Development. 2000 Jun ;127(12):2663-72.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to:

Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings from an open trial.

Source

Abstract

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Supplemental Content

Save items

Related citations in PubMed

Cited by 3 PubMed Central articles

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information